Session Recording from PHA's 2012 10th International PH Conference
PDE-5 Inhibitors and Endothelin Receptor Antagonists
June 23, 2012
This session will cover the phosphodiesterase inhibitors (PDE-5 inhibitors) (sildenafil, tadalafil) and their role in the treatment of pulmonary arterial hypertension. The mechanism of action of these drugs will be discussed as well as their potential benefits and associated risks. The evidence supporting their use will also be presented.
Richard Channick, MD, Massachusetts General Hospital, Boston, Mass. (Chair); Adaani Frost, MD, Baylor College of Medicine, Houston, Texas; Sandra Lombardi, RN, UCSD Medical Center, Encinitas, Calif.; Srinivas Murali, MD, West Penn Allegheny Health System, Pittsburgh, Pa.